Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Pediatric Endocrinology and Metabolism

Editor-in-Chief: Kiess, Wieland

Ed. by Bereket, Abdullah / Darendeliler, Feyza / Dattani, Mehul / Gustafsson, Jan / Luo, Fei Hong / Mericq, Veronica / Toppari, Jorma


IMPACT FACTOR 2018: 1.239

CiteScore 2018: 1.22

SCImago Journal Rank (SJR) 2018: 0.507
Source Normalized Impact per Paper (SNIP) 2018: 0.562

Online
ISSN
2191-0251
See all formats and pricing
More options …
Volume 29, Issue 7

Issues

Children with severe Osteogenesis imperfecta and short stature present on average with normal IGF-I and IGFBP-3 levels

Heike Hoyer-Kuhn / Laura Höbing / Julia Cassens / Eckhard Schoenau / Oliver Semler
Published Online: 2016-04-18 | DOI: https://doi.org/10.1515/jpem-2015-0385

Abstract

Background: Osteogenesis imperfecta (OI) is characterized by bone fragility and short stature. Data about IGF-I/IGFBP-3 levels are rare in OI. Therefore IGF-I/IGFBP-3 levels in children with different types of OI were investigated.

Methods: IGF-I and IGFBP-3 levels of 60 children (male n=38) were assessed in a retrospective cross-sectional setting.

Results: Height/weight was significant different [height z-score type 3 versus type 4: p=0.0011 and weight (p≤0.0001)] between OI type 3 and 4. Mean IGF-I levels were in the lower normal range (mean±SD level 137.4±109.1 μg/L). Mean IGFBP-3 measurements were in the normal range (mean±SD 3.105±1.175 mg/L). No significant differences between OI type 3 and 4 children have been observed (IGF-I: p=0.0906; IGFBP-3: p=0.2042).

Conclusions: Patients with different severities of OI have IGF-I and IGFBP-3 levels in the lower normal range. The type of OI does not significantly influence these growth factors.

Keywords: IGF-I; Osteogenesis imperfecta; short stature; srowth hormone

References

  • 1.

    Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 2004;363:1377–85.Web of ScienceGoogle Scholar

  • 2.

    Marini JC, Blissett AR. New genes in bone development: what’s new in osteogenesis imperfecta. J Clin Endocrinol Metab 2013;98:3095–103.Google Scholar

  • 3.

    Ben Amor IM, Glorieux FH, Rauch F. Genotype-phenotype correlations in autosomal dominant osteogenesis imperfecta. J Osteoporos 2011;2011:540178.Google Scholar

  • 4.

    Sillence DO. Osteogenesis imperfecta nosology and genetics. Ann N Y Acad Sci 1988;543:1–15.Google Scholar

  • 5.

    Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 2003;111(5 Pt 1):1030–6.Google Scholar

  • 6.

    Antoniazzi F, Bertoldo F, Mottes M, Valli M, Sirpresi S, et al. Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis. J Pediatr 1996;129:432–9.Google Scholar

  • 7.

    Kruse HP, Kuhlencordt F. On an attempt to treat primary and secondary osteoporosis with human growth hormone. Horm Metab Res 1975;7:488–91.Google Scholar

  • 8.

    Marini JC, Bordenick S, Heavner G, Rose S, Chrousos GP. Evaluation of growth hormone axis and responsiveness to growth stimulation of short children with osteogenesis imperfecta. Am J Med Genet 1993;45:261–4.Google Scholar

  • 9.

    Marini JC, Bordenick S, Heavner G, Rose S, Hintz R, et al. The growth hormone and somatomedin axis in short children with osteogenesis imperfecta. J Clin Endocrinol Metab 1993;76:251–6.Google Scholar

  • 10.

    Wright NM. Just taller or more bone? The impact of growth hormone on osteogenesis imperfecta and idiopathic juvenile osteoporosis. J Pediatr Endocrinol Metab 2000;13(Suppl 2):999–1002.Google Scholar

  • 11.

    Blum WF, Cao D, Hesse V, Fricke-Otto S, Ross JL, et al. Height gains in response to growth hormone treatment to final height are similar in patients with SHOX deficiency and Turner syndrome. Horm Res 2009;71:167–72.Google Scholar

  • 12.

    Land C, Blum WF, Stabrey A, Schoenau E. Seasonality of growth response to GH therapy in prepubertal children with idiopathic growth hormone deficiency. Eur J Endocrinol 2005;152:727–33.Google Scholar

  • 13.

    Hindmarsh PC, Dattani MT. Use of growth hormone in children. Nat Clin Pract Endocrinol Metab 2006;2:260–8.Google Scholar

  • 14.

    Poidvin A, Touze E, Ecosse E, Landier F, Bejot Y, et al. Growth hormone treatment for childhood short stature and risk of stroke in early adulthood. Neurology 2014;83:780–6.Google Scholar

  • 15.

    Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, et al. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 2005;20:758–63.Google Scholar

  • 16.

    Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994;15:80–101.Google Scholar

  • 17.

    Veilleux LN, Lemay M, Pouliot-Laforte A, Cheung MS, Glorieux FH, et al. Muscle anatomy and dynamic muscle function in osteogenesis imperfecta type I. J Clin Endocrinol Metab 2013;99:E356–62.Google Scholar

  • 18.

    Bikle DD, Tahimic C, Chang W, Wang Y, Philippou A, et al. Role of IGF-I signaling in muscle bone interactions. Bone 2015;80:79–88.Web of ScienceGoogle Scholar

  • 19.

    Frost HM, Schonau E. The “muscle-bone unit” in children and adolescents: a 2000 overview. J Pediatr Endocrinol Metab 2000;13:571–90.Google Scholar

  • 20.

    Wu QQ, Chen Q. Mechanoregulation of chondrocyte proliferation, maturation, and hypertrophy: ion-channel dependent transduction of matrix deformation signals. Exp Cell Res 2000;256:383–91.Google Scholar

About the article

Corresponding author: Priv.-Doz. Dr. med. Oliver Semler, Children’s Hospital, University of Cologne, Kerpenerstr. 62, 50937 Cologne, Germany, Phone: +49-221-478-84755, Fax: +49-221-478-1422311


Received: 2015-09-25

Accepted: 2016-03-07

Published Online: 2016-04-18

Published in Print: 2016-07-01


Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission. The corresponding author confirms that he had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Research funding: We thank “Deutsche Gesellschaft für Osteogenesis imperfecta (Glasknochen) Betroffene e.v.” including “Stiftung Baden-Württemberg” for financial research support.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


Citation Information: Journal of Pediatric Endocrinology and Metabolism, Volume 29, Issue 7, Pages 813–818, ISSN (Online) 2191-0251, ISSN (Print) 0334-018X, DOI: https://doi.org/10.1515/jpem-2015-0385.

Export Citation

©2016 by De Gruyter.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Si Chen, Yiman Tang, Yunsong Liu, Ping Zhang, Longwei Lv, Xiao Zhang, Lingfei Jia, and Yongsheng Zhou
Cell Proliferation, 2019
[2]
Y. Ohata, S. Takeyari, Y. Nakano, T. Kitaoka, H. Nakayama, V. Bizaoui, K. Yamamoto, K. Miyata, K. Yamamoto, M. Fujiwara, T. Kubota, T. Michigami, K. Yamamoto, T. Yamamoto, N. Namba, K. Ebina, H. Yoshikawa, and K. Ozono
Osteoporosis International, 2019

Comments (0)

Please log in or register to comment.
Log in